Medical Malpractice Liability Reform: H.R. 5, 109th Congress

name redacted
Legislative Attorney
American Law Division

Summary

H.R. 5, 109th Congress, which the House passed without amendment on July 28, 2005, would preempt state law regarding some aspects of medical malpractice liability, and liability for defective medical products, including drugs. It would not, however, preempt any state law that imposes greater procedural or substantive protections for health care providers and health care organizations from liability. In medical malpractice and defective medical products suits, H.R. 5 would, among other things, place caps on noneconomic and punitive damages (but only in states that have not enacted and do not enact caps), eliminate joint and several liability, modify the collateral source rule, limit lawyers’ contingent fees, enact a federal statute of limitations, and provide for periodic payment of future damages.

Preemption of State Laws

Medical malpractice suits are governed by state law, but, because they affect interstate commerce, the U.S. Constitution would permit Congress to regulate them and to preempt state laws that regulate them. H.R. 5, 109th Congress, the Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2005, would impose federal standards on some aspects of medical malpractice suits, but would leave other aspects to continue to be governed by state law.1 Actually, H.R. 5 would apply to all “health care liability claims,” which it defines to include not only medical malpractice suits, but product liability suits that allege injuries resulting from defective medical products.2

---

1 H.R. 5, 109th Congress, had previously been introduced in the 109th Congress as H.R. 534. It is virtually identical to H.R. 5, 108th Congress, and H.R. 4280, 108th Congress, which were both passed by the House. Those two bills were identical to each other except for one non-substantive word change. H.R. 5, 109th Congress, is similar to, but has several substantive differences from, S. 354, 109th Congress; for information on S. 354, see CRS Report RS22075, Medical Malpractice Liability Reform: S. 354, 109th Congress, by (name redacted).

2 The phrase “medical malpractice” in this report, when used in reference to H.R. 5, should be (continued...)
This report will summarize the main provisions of H.R. 5, and will do so not in the order of the bill’s sections, but in the order of the following subjects that the bill addresses: (1) cap on noneconomic damages, (2) standard for and cap on punitive damages, (3) limiting joint and several liability, (4) modifying the collateral source rule, (5) limiting lawyers’ contingent fees, (6) creating a federal statute of limitations, and (7) periodic payment of future damages. Another CRS report, without making reference to any particular legislation, discusses these same subjects in the same order, explaining the legal concepts each involves (in greater depth than the present report does) and offering pros and cons of each.3

Even with respect to those aspects of medical malpractice suits on which H.R. 5 would impose federal standards, H.R. 5 would not preempt every state law. It would not preempt any state law “that imposes greater procedural or substantive protections for health care providers and health care organizations from liability, loss, or damages than those provided by this act or create a cause of action” (§ 11(b)).4 It would also not preempt “any State law (whether effective before, on, or after the date of enactment of this act) that specifies a particular monetary amount of compensatory or punitive damages (or the total amount of damages) that may be awarded in a health care lawsuit, regardless of whether such monetary amount is greater or lesser than is provided for under this act . . .” (§ 11(c)).5

(1) Cap on Noneconomic Damages

H.R. 5 (§ 4(b)) would impose a $250,000 cap on noneconomic damages in any health care lawsuit, “regardless of the number of parties against whom the action is brought or the number of separate claims or actions brought with respect to the same injury.” As noted above, this cap would apply only in states that have no cap before enactment of H.R. 5 and that do not enact one subsequently.6

Economic damages refer to monetary losses that result from an injury, such as medical expenses, lost wages, and rehabilitation costs; H.R. 5 would not cap economic damages. Noneconomic damages consist primarily of damages for pain and suffering.

---

2 (...continued)
read to include all “health care liability claims.”


4 This provision does not mention sellers of medical products, but it seems likely that the bill is intended to preempt state law in suits alleging an injury caused by a defective medical product.

5 This provision raises the question whether a state that wishes to have no cap may enact a cap that is so high — say, $1 billion — that it is effectively no cap, and thereby not be subject to the bill’s cap.

6 H.R. 5 (§ 4(c)) provides that, for purposes of applying the $250,000 cap, “future noneconomic damages shall not be discounted to present value.” This apparently means that, if a jury awards, say, $260,000 in future noneconomic damages, and such amount could be paid in the form of an annuity that costs $240,000, the higher figure would control, and the future noneconomic damages would be reduced to $250,000, not to $240,000.
Both economic and noneconomic damages are compensatory damages, as opposed to punitive damages.

(2) Standard for and Cap on Punitive Damages

H.R. 5 (§ 7(a)) provides that punitive damages may be awarded if otherwise permitted by state law, if the claimant proves “by clear and convincing evidence” that the defendant “acted with malicious intent to injure the claimant, or . . . deliberately failed to avoid unnecessary injury that [the defendant] knew the claimant was substantially certain to suffer.” H.R. 5 would thus preempt state law regarding the burden of proof and standard for awarding punitive damages, except in states that provide greater protection for defendants. 7

H.R. 5 (§ 7(b)(2)) would also impose a cap on punitive damages of $250,000 or two times the amount of economic (not of all compensatory) damages awarded, whichever is greater. As with H.R. 5’s cap on noneconomic damages, the cap on punitive damages would apply only in states that have no cap before enactment of H.R. 5 and that do not enact one subsequently.

H.R. 5 (§ 7(c)(1)) would provide that “[n]o punitive damages may be awarded against the manufacturer or distributor of a medical product, or a supplier of any component or raw material of such medical product,” if the product has been approved by the Food and Drug Administration or is generally recognized as safe and effective under FDA regulations. This prohibition of punitive damages would not apply, however, if a person (1) “knowingly misrepresented to or withheld from the Food and Drug Administration information that is required to be submitted . . . that is causally related to the harm which the claimant allegedly suffered,” or (2) made an illegal payment to an official of the Food and Drug Administration for the purpose of either securing or maintaining approval, clearance, or licensure of such medical product.” FDA regulations require that, even after a drug is approved, drug companies report to the FDA new information they obtain about adverse drug experiences. 8 Therefore, a company that fails to do so could, under the bill, apparently be subject to punitive damages, state law permitting.

(3) Limiting Joint and Several Liability

H.R. 5 (§ 4(d)) would eliminate joint and several liability in medical malpractice suits. Joint and several liability is the common-law rule that, if more than one defendant is found liable for a plaintiff’s injuries, then each defendant may be held 100 percent liable. With joint and several liability, the plaintiff may not recover more than once, but may recover all his or her damages from fewer than all liable defendants, with any defendant who pays more than its share of the damages entitled to seek contribution from other liable defendants.

7 See CRS Report RL31721, Punitive Damages in Medical Malpractice Actions: Burden of Proof and Standards for Awards in the Fifty States, by (name redacted) and Tara Alexandria Rainson.

8 21 C.F.R. § 314.80(b),(c), § 314.81(b)(2).
The main argument for eliminating joint and several liability is that it allows a plaintiff to recover his entire damage award from a “deep pocket” defendant who was only minimally liable. The main argument for retaining joint and several liability is that it is preferable for a wrongdoer to pay more than its share of the damages than for an injured plaintiff to recover less than the full compensation to which he is entitled.

(4) Modifying the Collateral Source Rule

The collateral source rule is the common-law rule that allows an injured party to recover damages from the defendant even if he is also entitled to receive them from a third party (a “collateral source”), such as a health insurance company, an employer, or the government. To abolish the collateral source rule would be to require courts to reduce damages by amounts a plaintiff receives or is entitled to receive from collateral sources.

Often a collateral source, such as a health insurer or the government, has a right of subrogation against the tortfeasor (the person responsible for the injury). This means that the collateral source takes over the injured party’s right to sue the tortfeasor, for up to the amount the collateral source owes or has paid the injured party. Though the collateral source rule may enable the plaintiff to recover from both his insurer and the defendant, the plaintiff, if there is subrogation, must reimburse his insurer the amount it paid him. If the collateral source rule were eliminated, then the defendant would not have to pay the portion of damages covered by a collateral source, and the collateral source would apparently not be able through subrogation to recover the amount it paid the plaintiff. In the medical malpractice context, therefore, eliminating the collateral source rule would benefit liability insurers at the expense of health insurers and other collaterals sources.

H.R. 5 (§ 6) would provide that, in any health care lawsuit, any party (usually the defendant) may introduce evidence of collateral source benefits, and the opposing party (usually the plaintiff) may introduce evidence of amounts paid to secure those benefits (e.g., health insurance premiums). H.R. 5 does not state that collateral source benefits, minus amounts paid to secure such benefits, would have to be deducted from damage awards.

H.R. 5 would also eliminate the right of subrogation. In cases in which collateral source benefits are deducted from damage awards, the plaintiff would not recover any money from the defendant against which the collateral source would have a right of subrogation, even if H.R. 5 did not eliminate the right of subrogation. In cases in which collateral source benefits are not deducted, the plaintiff could apparently recover from both the defendant and the collateral source.

(5) Limiting Lawyers’ Contingent Fees

A contingent fee is one in which a lawyer, instead of charging an hourly fee for his services, agrees, in exchange for representing a plaintiff in a tort suit, to accept a percentage of the recovery if the plaintiff wins or settles, but to receive nothing if the plaintiff loses. Payment is thus contingent upon there being a recovery. Plaintiffs agree to this arrangement in order to afford representation without having to pay anything out-of-pocket. Lawyers agree to it, despite the risk of not being compensated, because the
percentage they receive if they win or settle — usually from 33\% to 40 percent — generally amounts to more than an hourly fee would.

H.R. 5 (§ 5) would impose a cap with a sliding scale in medical malpractice cases: 40% of the first $50,000 the plaintiff recovered, 33\% of the next $50,000, 25% of the next $500,000, and 15% of any additional amount.

(6) Creating a Federal Statute of Limitations

The statute of limitations — the period within which a lawsuit must be filed — for medical malpractice suits under state law is typically two or three years, starting on the date of injury. Sometimes, however, the symptoms of an injury do not appear immediately, or even for years after, malpractice occurs. Many states therefore have adopted a “discovery” rule, under which the statute of limitations starts to run only when the plaintiff discovers, or in the exercise of reasonable diligence should have discovered, his injury — or, sometimes, his injury and its cause.

H.R. 5 (§ 3) provides:

The time for the commencement of a health care lawsuit shall be three years after the date of manifestation of injury or one year after the claimant discovers, or through the use of reasonable diligence should have discovered, the injury, whichever occurs first. In no event shall the time for commencement of a health care lawsuit exceed three years after the date of manifestation of injury unless tolled [i.e., the three years does not start to run] for any of the following — (1) upon proof of fraud; (2) intentional concealment; or (3) the presence of a foreign body, which has no therapeutic or diagnostic purpose or effect, in the person of the injured person.

This provision, rather than imposing a time limitation that begins on the date of injury or on the date of discovery of the injury, would cut off the right to sue upon the earlier of two different periods — three years and one year — that begin, respectively, on the date of manifestation of injury and discovery of the injury. H.R. 5 defines neither term, but, in its report on the 108th Congress’s identical bill, the House Committee on Energy and Commerce explained the former term: “The term ‘manifestation of injury’ means the injury has become reasonably evident. Thus, if someone unknowingly receives tainted blood, ‘manifestation of injury’ is not the date of receiving the blood. Instead, it is the date on which adverse symptoms become reasonably evident.”9

The discovery of the injury, then, would apparently occur on the date that the patient learns that his blood is tainted, which date may not occur until after “manifestation of injury.” Suppose that medical tests reveal the tainted blood one year after the plaintiff experienced his first symptoms. There would still be two years to run on the three-year manifestation period, but the plaintiff would apparently have to sue within one year of discovering that his blood is tainted — even if it takes more than one year to learn that his blood is tainted as a result of a transfusion. A patient could also apparently discover his injury, perhaps through a routine medical test, before symptoms become manifest, and, again, the one-year discovery period would apparently apply.

---

It is not clear whether this provision is, strictly speaking, a statute of limitations. (H.R. 5 does not call it that.) A statute of limitations is typically an affirmative defense, which means that the defendant must raise it; if the defendant fails to raise it, then the plaintiff may sue regardless of how much time has passed.\(^\text{10}\) H.R. 5, by contrast, could be interpreted to place the burden of proof on the plaintiff to show that his injury occurred within the time period allowed.

(7) Periodic Payment of Future Damages

Traditionally, damages are paid in a lump sum, even if they are for future medical care or future lost wages. In recent years, however, “attorneys for both parties in damages actions have occasionally foregone lump-sum settlements in favor of structured settlements, which give the plaintiff a steady series of payments over a period of time through the purchase of an annuity or through self-funding by an institutional defendant.”\(^\text{11}\)

H.R. 5 (§ 8) provides:

In any health care lawsuit, if an award of future damages, without reduction to present value, equaling or exceeding $50,000, is made against a party with sufficient insurance or other assets to fund a periodic payment of such a judgment, the court shall, at the request of any party, enter a judgment ordering that the future damages be paid by periodic payments. In any health care lawsuit, the court may be guided by the Uniform Periodic Payment of Judgments Act promulgated by the National Conference of Commissioners on Uniform State Law.

Though this provision states that an award of future damages shall not be reduced to present value to determine whether it equals or exceeds the $50,000 minimum necessary for a party to require the court to order periodic payments, it does not state whether the amount of the award of future damages would be converted to present value. Not to require such conversion “could be a very major change, significantly reducing awards, if it is intended to allow a defendant to pay, for example, a $1 million award over a 10-year period at $100,000 a year. On the other hand, if it requires the jury award to be converted into present value terms — an annuity with a present value of $1 million — the reform doesn’t mean that much; as a practical matter, the defendant would be paying the same amount as before.”\(^\text{12}\) The defendant, that is, would have to spend $1 million for an annuity that, as it earned interest over the years of its distribution, would yield the plaintiff more than $1 million. Had the defendant paid the plaintiff a lump sum of $1 million, then the plaintiff could have purchased that same annuity.

---

\(^{10}\) See, e.g., Federal Rule of Civil Procedure 8(c).

\(^{11}\) Annotation, Propriety and Effect of “Structured Settlements” Whereby Damages are Paid in Installments Over a Period of Time, and Attorneys’ Fees Arrangements in Relation Thereto, 31 ALR4th 95, 96.

The Congressional Research Service (CRS) is a federal legislative branch agency, housed inside the Library of Congress, charged with providing the United States Congress non-partisan advice on issues that may come before Congress.

EveryCRSReport.com republishes CRS reports that are available to all Congressional staff. The reports are not classified, and Members of Congress routinely make individual reports available to the public.

Prior to our republication, we redacted names, phone numbers and email addresses of analysts who produced the reports. We also added this page to the report. We have not intentionally made any other changes to any report published on EveryCRSReport.com.

CRS reports, as a work of the United States government, are not subject to copyright protection in the United States. Any CRS report may be reproduced and distributed in its entirety without permission from CRS. However, as a CRS report may include copyrighted images or material from a third party, you may need to obtain permission of the copyright holder if you wish to copy or otherwise use copyrighted material.

Information in a CRS report should not be relied upon for purposes other than public understanding of information that has been provided by CRS to members of Congress in connection with CRS' institutional role.

EveryCRSReport.com is not a government website and is not affiliated with CRS. We do not claim copyright on any CRS report we have republished.